DNTH Dianthus Therapeutics, Inc. /DE/companySEC Filings & Insider Trading Activity 2026
Latest Dianthus Therapeutics, Inc. /DE/ (DNTH) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on March 26, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Dianthus Therapeutics, Inc. /DE/ (DNTH) (SEC CIK 1690585), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Development of claseprubart and DNTH212 biopharmaceutical candidates reliant on outsourced manufacturing and clinical trial services
- • New emphasis: Impact of the BIOSECURE Act (Dec 2025) restricting collaborations with certain Chinese biotech firms, including sole manufacturer WuXi Biologics
Risk Factors
- • Regulatory risk: Dependence on FDA approval for claseprubart and DNTH212 with uncertain timing and outcomes for clinical trial phases and marketing approvals
- • Geopolitical risk: License and development agreements with Tenacia Biotechnology for Greater China involving clinical trial cost sharing and milestone payments up to $15 million
Management Discussion & Analysis
- • No revenue reported, no year-over-year change disclosed
- • Net loss reported; specific profitability or margin figures not provided
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • No new or updated risks disclosed this quarter compared to 10-K ended December 31, 2024
- • Continued risk of material harm to business and stock price decline from events described in 10-K risks
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Offering priced at $81.00/share; 7.31M shares + 402K pre-funded warrants issued, with full 1.16M share overallotment exercised next day
- • Net proceeds ~$673.5M after underwriting discounts and offering expenses
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 9, 2026 — full financials in Exhibit 99.1
- • Filing "furnished" not "filed" — standard for earnings releases, limits legal liability under Exchange Act
Item 7.01: Regulation FD Disclosure
- • Phase 3 CAPTIVATE trial of claseprubart in CIDP received early "GO" decision following interim responder analysis
- • GO decision signals pre-specified efficacy threshold met mid-trial — typically a strong positive catalyst for clinical-stage biotech
Item 8.01: Other Events
- • Dianthus filed multiple exhibits on March 9, 2026, including a dedicated data press release and data presentation — signals clinical or preclinical trial results disclosed
- • Dual data releases (99.2 + 99.3) suggest structured presentation of study findings, likely for an investor/medical conference or regulatory milestone
Annual Reports Archive10-K
AI-powered analysis of Dianthus Therapeutics, Inc. /DE/ (DNTH) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Dianthus Therapeutics, Inc. /DE/ (DNTH) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Dianthus Therapeutics, Inc. /DE/ (DNTH) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Profitability | |||||
| Revenue | — | — | $2.8M | $6.2M | $2.0M |
| Operating Income | — | -$80.9M | -$48.2M | -$101.9M | -$177.9M |
| Net Income | — | -$76.5M | -$43.6M | -$85.0M | -$162.3M |
| Op. Margin | — | — | -1704.7% | -1633.7% | -8739.3% |
| Net Margin | — | — | -1541.2% | -1362.8% | -7973.3% |
| Balance Sheet | |||||
| Total Assets | $189.9M | $146.6M | $179.4M | $374.0M | $530.9M |
| Equity | — | $106.0M | $168.9M | $352.5M | $493.4M |
| ROE | — | -72.2% | -25.8% | -24.1% | -32.9% |
Source: XBRL financial data from Dianthus Therapeutics, Inc. /DE/ (DNTH) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 26, 2026 | — | — | — |
8-K | Mar 12, 2026 | — | Analysis | — |
10-K | Mar 9, 2026 | Dec 31, 2025 | Analysis | |
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 11, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Mar 21, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 15, 2023 | Mar 31, 2023 | — | |
10-K | Mar 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 16, 2022 | Mar 31, 2022 | — | |
10-K | Mar 8, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Mar 3, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest DNTH SEC filings in 2026?
Dianthus Therapeutics, Inc. /DE/ (DNTH) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 26, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did DNTH file its most recent 10-K annual report?
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view DNTH 10-Q quarterly reports?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every DNTH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has DNTH filed recently?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s most recent 8-K was filed on March 26, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find DNTH insider trading activity (Form 4)?
SignalX aggregates every DNTH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does DNTH file with the SEC?
Dianthus Therapeutics, Inc. /DE/ (DNTH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DNTH filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Dianthus Therapeutics, Inc. /DE/ (DNTH).
What is DNTH's SEC CIK number?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s SEC CIK (Central Index Key) number is 1690585. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1690585 to look up all DNTH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find DNTH return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Dianthus Therapeutics, Inc. /DE/ (DNTH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Dianthus Therapeutics, Inc. /DE/ SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 35+ filings.